Theres another wayand it starts small.
If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration
Keywords: GLP-1 receptor agonists, obesity, weight loss, non-diabetic patients, cardiovascular outcomes, cost-effectiveness Introduction Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern [7] [8]
State employee plans and federal employee plans often have better coverage than individual market plans
Peripheral serotonin synthesis as a new drug target
